Skip To Main Content
Rajat Bannerji on Muck Rack

Rajat Bannerji

As seen in: Wiley Online Library, The Lancet, Patient Power
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rajat

Contact Rajat, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclonal antibody in relapsed/refractory B‐cell non‐Hodgkin lymphoma

|
By Sam Yuen, Tycel J. Phillips, Rajat Bannerji, Paula Marlton
| Wiley Online Library Verified
1 INTRODUCTION Advanced-stage follicular lymphoma (FL) has recurrent relapses and is incurable with standard treatments.1 Diffuse large B-cell lymphoma (DLBCL), although potentially curable with initial anthracycline-based chemoimmunotherapy, presents as relapsed/refractory (R/R) disease in 40% of patients.1 Therefore, novel treatment options with improved efficacy and safety are needed for these B-cell non-Hodgkin lymphoma (NHL) subtypes.
Open in Who Shared Issue with article?

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R NHL: Results from preclinical models and a Phase Ib study

|
By Elisabeth A. Lasater, Dhara Amin, Rajat Bannerji, Kathy Barrett
| Wiley Online Library Verified
RESEARCH ARTICLE This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ajh.26809. Abstract The treatment of patients with relapsed or refractory lymphoid neoplasms represents a significant clinical challenge.
Open in Who Shared Issue with article?

Evening With the Docs: Rutgers Cancer Institute

|
By Rajat Bannerji, Seth Cohen
| Patient Power Verified
Latest CLL Updates From the Rutgers Cancer Institute With all of the new information being released, understanding chronic lymphocytic leukemia (CLL) research findings and treatment choices can be difficult.
Open in Who Shared Issue with article?
See all 4 articles